Skip to main
STRO

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 0%
Sell 17%
Strong Sell 0%

Bulls say

Sutro Biopharma Inc. demonstrates a strong potential for growth through its innovative product candidates, particularly STRO-004, which promises enhanced clinical benefits and safety compared to existing alternatives in the antibody-drug conjugate (ADC) market. The company has showcased a solid history in designing ADCs with minimal eye toxicity and exhibited operational consistency across its pipeline, reinforcing confidence in its proprietary XpressCF platform's capacity to produce therapeutics with improved drug exposures and tolerability. Additionally, insights from key opinion leaders suggest that STRO-004’s preclinical safety metrics and unique attributes position it favorably in the competitive landscape, enhancing its likelihood of gaining market traction and addressing historical challenges in ADC treatments.

Bears say

Sutro Biopharma, Inc. faces significant challenges due to the prevailing issues related to ocular toxicity associated with antibody-drug conjugates (ADCs), which hinder physician adoption and patient agreement to treatment. The clinical concerns are compounded by the lengthy delays patients experience in obtaining specialized care for ocular toxicities, leading to frequent treatment interruptions for 15-20% of patients. Additionally, uncertainties surrounding the role of pseudokinases in cancer biology raise concerns about the effectiveness of targeting these proteins, thus contributing to the negative outlook on the company's future performance.

STRO has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Buy based on their latest research and market trends.

According to 6 analysts, STRO has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.63, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.63, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.